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Background: We investigated the long-term effects and safety of botulinum toxin-A (BTX-A) for treating trigeminal
neuralgia (TN). We also studied long-term maintenance of this therapeutic effect.
Methods: A visual analog scale (VAS) score, pain attack frequency per day, patient’s overall response to treatment
and side effects during 14-month follow-up were evaluated in 88 patients with TN receiving BTX-A. The primary
endpoints were pain severity (assessed by VAS) and pain attack frequency per day. The secondary endpoint was the
patient’s overall response to treatment, assessed using the Patient Global Impression of Change. The influence of
different doses (≤50, 50–100 and ≥100 U) on the therapeutic effect was evaluated.
Results: Treatment was deemed “effective” within 1 month in 81 patients and at 2 months in 88 patients (100%).
The shortest period of effective treatment was 3 months, and complete control of pain was observed in a
maximum of 46 patients. The therapeutic effect decreased gradually after 3 months, and the prevalence of effective
treatment at 14 months was 38.6%, with complete control of pain seen in 22 patients (25%). There was no
significant difference in the prevalence of effective treatment between different dose groups at identical time
points (p > 0.05). Three patients showed swelling at injection sites and 10 patients showed facial asymmetry, both
of which disappeared spontaneously without special treatment.
Conclusion: Local subcutaneous injection of BTX-A for TN treatment has considerable therapeutic effects lasting
several months and is safe for this indication. At least one-quarter of patients maintained complete analgesia.
The maintenance period of the therapeutic effect may be related to the reduction in the VAS score after the first
injection of BTX-A.
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Trigeminal neuralgia (TN) is characterized by sudden
(usually unilateral), severe, brief, stabbing, recurrent pain in
the distribution of one or more branches of the trigeminal
nerve. TN is usually evoked by the stimulation of facial
“trigger points”, such as teeth-brushing, face-washing,
drinking, or shaving. Because the pain is long-term and se-
vere, the quality of life of patients is severely affected [1].* Correspondence: lianyajun840317@163.com
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in any medium, provided the original work is pBotulinum toxin A (BTX-A) is a type of exotoxin
produced by Clostridium botulinum. It relaxes muscles
through the release of acetylcholine at nerve–muscle
junctions. Therefore, BTX-A is used widely in cosmet-
ology and treating dysmyotonia [2]. BTX-A can also in-
hibit secretion from glands through inhibition of the
release of acetylcholine from cholinergic nerve terminals
[3]. It is used in the treatment of bromhidrosis, hyperhi-
drosis, hygrostomia, vasomotor rhinitis, and rhinorrhea.
Recently, the use of BTX-A for pain management has
received considerable attention. In 2002, Micheli et al.
were the first to report that BTX-A can relieve TN [4].
Subsequent reports also supported the beneficial effectsen Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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tion period of the therapeutic effect of BTX-A in TN is
6 months [7,8]. In a review focusing on BTX for the
treatment of neuropathic pain, the longest observation
period for BTX-A in TN was 4 months [9]. Reports fo-
cusing on longer observation periods or factors related
to the maintenance of long-term effects are lacking.
Here, we report the effect of BTX-A in the treatment of
88 TN patients with a follow-up of 14 months.Methods
Ethical approval of the study protocol
The study protocol was approved by the Ethics Committee
of Zhengzhou University (Zhengzhou, China). All patients
provided written informed consent to participate in the
study.Patient recruitment
We conducted an open study. Eighty-eight subjects with
primary one-branch classical TN treated with BTX-A
were recruited as outpatients or inpatients from the
Neurology Department of the First Affiliated Hospital,
Zhengzhou University from January 2009 to June 2012.
The goal, procedure and safety aspects of the study were
explained to each of the patients and Informed consent
was included in the documents of each patient. The
medications which were used to alleviate their pain were
asked to remain unchanged during the course of the study.
All patients showed symptom improvement after 8 weeks
of treatment, and were followed up for 12 months. And for
some patients who didn’t show symptom improvement
within 2–4 weeks,we gave an additional dose, and plus the
additional dose for the first dose as the treatment dose. The
patients who showed improvement after 8 weeks of re-
injection were followed up for 12 months too. Before
hospital admission, all patients underwent laboratory
examinations to exclude coagulation disorders and se-
vere dysfunction of the heart, liver or kidneys. Detailed
physical examinations as well as CT and MRI of the
cranium were conducted to exclude secondary TN.Therapeutic regimens
BTX-A crystals (HengLi®; 100 U/bottle; Lanzhou Biopro-
duction Institute, Lanzhou, China) was diluted with 0.9%
saline (2 mL) to 50 U/mL before use. The BTX-A solu-
tion was injected in the facial area and the trigger point
of pain at a depth of 0.5 cm, 2.5-5 IU per point, separ-
ation of 15 mm and at 15–20 injection points. And for
some patients the pain within one side of gum, the injec-
tion points were 4–10,and because the gingival mucosa
is thinner than skin, the dosage were fewer than facial
area in each point.Observation indices and evaluation of therapeutic effects
Information regarding pain (including the extent of pain,
pain attack frequency,and side effects) was recorded in
detail each day by patients before and after therapy.
Clinic visits or telephone follow-up were undertaken by
the same person every week for 2 months and every
month thereafter. The patient’s overall response to treat-
ment was followed up each month after therapy. The ex-
tent of pain was evaluated through a visual analog scale
(VAS) with 11 points on a ruler of length 10 cm where 0
denoted “no pain” and 10 denoted “most severe pain”.
Patients pointed to the representive point of pain on the
panel without reading it but instead according to their
feelings, and the corresponding pain scores were re-
corded. We adopted the classification that a reduction in
the VAS score of <50% after treatment meant that treat-
ment was classified as being “ineffective”, 50–70% as “ef-
fective”, >75% as “significantly effective” and “0” meant
that pain was “completely controlled”. The total effective
value was defined as the percentage of patients with a
reduction in the VAS score of ≥50%. The patient’s overall
response to treatment assessed using the Patient Global
Impression of Change. PCIC is a single-item rating by
patients of their improvement with treatment during the
therapy on a 7-point scale that ranges from ‘very much
improved’ to ‘very much worse’ with ‘no change’ as the
mid-point.
Side effects
Information regarding side effects (time, extent, dur-
ation, frequency, treatment, outcomes of treatment, and
correlation with treatment) was recorded in detail.
Statistical analyses
Data are the mean ± SD and were analyzed using SPSS
ver20.0 (SPSS, Chicago, IL, USA). The effective value




The patient cohort comprised 38 males (43.2%) and 50
females (56.8%). The age range was 33–89 years (mean,
60.6 years; SD = 11.90). Disease progression was 14–150
months with mean of 52 months and SD of 50.17. All 88
patients showed symptom improvement within 2 weeks.
The percentage of patients in whom treatment was ef-
fective at 2 months reached 100%.
Distribution of pain area
The pain area was in the first branch of the trigeminal
nerve in 19 cases, in the second branch in 42 cases, and
in the third branch in 27 cases.
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Maximal and minimal doses were 170 U and 25 U, re-
spectively. The dose was ≤50 U in 43 cases, 50–100 U in
32 cases, and ≥100 U in 13 cases.Therapeutic effect at different time points
Treatment was classified as being effective within 1 month
in 81 cases, and was effective at 2 months in 88 cases
(prevalence of effective treatment of 100%). All the patients
who showed symptoms improvement significantly reduced
pain attack frequency. TN was classified as being com-
pletely controlled at 3 months in 46 cases. The number of
cases in whom treatment was classified as being effective at
3 months decreased to 76, and the number of cases with a
reduction in the VAS score of 50–75% decreased from 30
to 17 at 2 months. After 3 months, the effect of BTX-A
decreased gradually, with a prevalence of effective
treatment of 38.6% at 14 months, and of TN being
completely controlled in 22 cases (25%) (Table 1).More
than 90% patients with effective treatment reported
that they were “much improved” or “very much im-
proved” each month (Table 2).Comparison of effective values and pain attack frequency
at different doses
There was no significant difference in the prevalence of
effective treatment between different dose groups at
identical time points between 1 month and 14 months
(p > 0.05) (Table 3).
There was no significant difference in the prevalence
of pain attack frequency between different dose groups
at identical time points between 1 month and 14 months
(p > 0.05) (Table 4).Table 1 Comparison of the prevalence of effective treatment
Time (months) Effective, % (no.) Significantly effective, % (no.)
1 31.8 (28) 18.2 (16)
2 34.1 (30) 19.3 (17)
3 19.3 (17) 14.8 (13)
4 9.1 (8) 13.6 (12)
5 8.0 (7) 12.5 (11)
6 8.0 (7) 9.1 (8)
7 6.8 (6) 9.1 (8)
8 5.7 (5) 10.2 (9)
9 6.8 (6) 8.0 (7)
10 3.4 (3) 9.1 (8)
11 2.3 (2) 9.1 (8)
12 3.4 (3) 9.1 (8)
13 6.8 (6) 8.0 (7)
14 8.0 (7) 5.7 (5)Doses for patients in whom treatment was effective only
at 3 months
The number of patients in whom treatment was effective
only at 3 months decreased from 88 to 76. The 12 pa-
tients in whom treatment was effective only for 3 months
comprised 4 cases receiving 25 U, 3 cases receiving 50
U, 2 cases receiving 75 U, 2 cases receiving 100 U, and 1
case receiving 125 U.
Side effects
Systemic side effects were not observed. Local swelling
at injection sites occurred in 3 patients and disappeared
within 7 days, 1 cases receiving 25 U, 1 cases receiving
75 U, 1 cases receiving 125 U. Muscle relaxation at injec-
tion sites occurred in 10 patients and disappeared within
6–8 weeks, 1 case receiving 45 U, 2 case receiving 50 U, 1
case receiving 70 U, 2 case receiving 75 U, 2 case receiv-
ing 100 U, 1 case receiving 120 U, 1 case receiving 125 U.
All side effects were mild and disappeared without the
need for further treatment.
Discussion
BTX-A has been used against neuropathic pain, includ-
ing post-herpetic neuralgia [10], diabetic neuropathic
pain [11], occipital neuralgia [12], TN [13] and chronic
facial pain [14]. The present study compared the effects
of 75 U BTX-A and placebo in the treatment of primary
TN for 8 weeks. BTX-A significantly decreased the VAS
score 1 week after BTX-A injection and the effect con-
tinued for 8 weeks, suggesting that multiple subcutane-
ous injections of BTX-A in the TN area can significantly
relieve pain [5]. Studies have suggested that injection of
BTX-A in an area near the zygomatic arch or masseter
muscle can also be effective [15,16].at different time points
Completely controlled, % (no.) Total effective value, % (no.)
42.0 (37) 92.0 (81)
46.6 (41) 100 (88)
52.3 (46) 86.4 (76)
50.0 (44) 72.7 (64)
50.0 (44) 70.5 (62)
46.6 (41) 63.6 (56)
42.0 (37) 58.0 (51)
37.5 (33) 53.4 (47)
37.5 (33) 52.3 (46)
37.5 (33) 50.0 (44)
36.4 (32) 47.7 (42)
31.8 (28) 44.3 (39)
25.0 (22) 39.8 (35)
25.0 (22) 38.6 (34)
Table 2 Comparison of the Patient Global Impression of Change (PGIC) in Patients with a reduction in the VAS score
of ≥50% at different time points
Time (months) Patients with a reduction in the VAS score of ≥50% (n) Very much improved (n1) Much improved (n2) n1+n2/n × 100%
1 81 45 32 95.06%
2 88 51 32 93.18%
3 78 60 13 93.59%
4 64 56 6 96.88%
5 62 53 8 98.39%
6 56 46 9 96.43%
7 51 42 6 94.12%
8 48 40 7 97.92%
9 46 39 5 95.66%
10 44 40 3 97.73%
11 42 39 2 97.62%
12 39 36 1 94.87%
13 35 30 3 94.28%
14 34 28 6 100%
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effective within 4 weeks in 81 cases, and within 4–8
weeks in 7 cases. These findings suggested that observa-
tion of ≥8 weeks is necessary for evaluation of thera-
peutic effects. Five cases showed a decreased VAS score
after 2 months and that their pain was completely con-
trolled at 3 months. These results suggest that the
therapeutic effect in some cases is slow. Micheli et al.
reported that recurrent facial spasm is accompanied
simultaneously by recurrent pain after 12 weeks in
patients with facial spasms complicated by TN [4].
Therefore, Micheli et al. proposed that the duration ofTable 3 Comparison of the prevalence of effective treatment
Time
(months)
≤50 U (n = 43) 50-100 U
Effective value, % (n) Effective v
1 88.4 (38) 93.8
2 100.0 (43) 100.
3 88.4 (38) 87.5
4 76.7 (33) 65.6
5 74.4 (32) 62.5
6 72.1 (31) 56.3
7 65.1 (28) 53.1
8 60.5 (26) 50.0
9 58.1 (25) 50.0
10 58.1 (25) 46.9
11 55.8 (24) 46.9
12 51.2 (22) 43.8
13 48.8 (21) 37.5
14 46.5 (20) 37.5the effect of BTX-A for treating TN is consistent with
its relaxation of muscle tension. In general, relaxation
of muscle tension by BTX-A can last for 3–6 months.
In the present study, the prevalence of effective treat-
ment at 6 months and 14 months was 63.6% and
38.6%, including 41 cases and 22 cases of completely
controlled pain, respectively. In 2012, we reported 1
case of TN without recurrence in 2 years [17], which is
beyond the period of relaxation of muscle tension elic-
ited by BTX-A. This finding suggests that BTX-A can
relieve pain for longer than it can relax muscle tension.
Therefore, we think that the analgesic effect of BTX-Aat different doses
(n = 32) ≥ 100 U (n = 13) p
alue, % (n) Effective value, % (n)
(30) 100.0 (13) 0.360
0 (32) 100.0 (13) ___
(28) 76.9 (10) 0.558
(21) 76.9 (10) 0.528
(20) 76.9 (10) 0.459
(18) 53.8 (7) 0.270
(17) 46.2 (6) 0.376
(16) 38.5 (5) 0.337
(16) 38.5 (5) 0.437
(15) 30.8 (4) 0.203
(15) 23.1 (3) 0.116
(14) 23.1 (3) 0.202
(12) 15.4 (2) 0.892
(12) 15.4 (2) 0.128
Table 4 Comparison of the prevalence of pain attack frequency at different doses
Time (months) ≤50 U (n = 43) 50-100 U (n = 32) ≥ 100 U (n = 13) p
Attack frequency, time/24 h Attack frequency, time/24 h Attack frequency, time/24 h
Before treatment 45.02 ± 85.56 30.40 ± 49.93 83.23 ± 119.49 0.872
1 4.72 ± 10.05 2.56 ± 4.58 1.92 ± 2.96 0.154
2 4.16 ± 9.49 1.63 ± 2.65 2.38 ± 2.87 0.122
3 2.15 ± 4.07 1.31 ± 2.39 1.42 ± 1.78 0.613
4 1.00 ± 2.14 1.43 ± 2.69 1.50 ± 1.90 0.528
5 1.00 ± 2.17 1.50 ± 2.74 1.40 ± 2.12 0.747
6 0.97 ± 2.15 1.33 ± 2.61 1.43 ± 2.44 0.908
7 0.54 ± 1.04 1.59 ± 2.92 2.5 ± 4.18 0.611
8 0.56 ± 1.05 1.50 ± 2.78 1.00 ± 2.24 0.735
9 0.52 ± 0.96 1.43 ± 2.76 2.00 ± 4.47 0.823
10 0.48 ± 0.96 1.00 ± 1.60 0.00 ± 0.00 0.338
11 0.46 ± 0.98 1.00 ± 1.60 0.00 ± 0.00 0.362
12 0.55 ± 1.01 0.71 ± 1.20 0.00. ± 0.00 0.570
13 0.62 ± 1.12 0.83 ± 1.27 2.00 ± 2.83 0.573
14 0.45 ± 0.89 0.75 ± 1.22 1.00 ± 1.41 0.663
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in nerve–muscle junctions.
With respect to the dose range, reports have suggested
values from 12.5 U to 100 U [9], with the range of 50–
100 U seeming to be the best. The dose range used in
the present study was 25–170 U. The patient mentioned
above who remained free of TN for 2 years was the first
patient with TN of the third branch that we treated
early. The VAS score was 10 and the dose of BTX-A was
170 U (which was the maximum dose we used in all TN
patients, she received an additional dose 10 days after
the first injection.). At 4 weeks, the VAS score was 0
and, unexpectedly, there was no pain for 3 years.
The present study suggests that there is no significant dif-
ference in the therapeutic effect and pain attack frequency
between different dose groups at identical time points be-
tween 1 month and 14 months. We also showed that effect-
ive treatment was observed within 1 month in 81 cases and
at 2 months in 88 cases. Effective treatment at 3 months
was observed in only 76 cases. That is, therapeutic effect
was maintained only for 3 months in 12 patients. The 12
cases showing a therapeutic effect only for 3 months were
those using all doses of BTX-A. Patients with a short-term
therapeutic effect were mainly those showing a decrease in
the VAS score after the first injection. Patients in whom
symptoms were completely controlled showed this effect at
3 months (46 cases), of which 14 cases showed no pain at
14 months. These results suggest that the factor influencing
the long-term effect of BTX-A is not dose but the extent of
the reduction of the VAS score. That is, the more the VAS
score decreases, the longer the therapeutic effect is main-
tained. Therefore, to reach complete control of symptomsand limit the minimal effective dose, we recommend a
small dose for the first injection and increase the dose after
2–4 weeks for those in whom complete control of symp-
toms after the first injection is not observed.
The mechanism of action of BTX-A in pain therapy is
not clear. Recent studies suggest that BTX-A can relieve
pain through inhibition of the release of cytokines from
sensory terminals and by reducing neurogenic inflamma-
tion [17]. This effect can be accomplished selectively
through inhibition of C-fibers and the transient receptor
potential vanilloid (TRPV)1 receptor [18], inhibition of
calcitonin gene-related peptide from trigeminal sensory
neurons in the brainstem [19], or decrease of peripheral
sensitization and central sensitization [20]. In addition,
the proposal regarding the existence of BTX-A-sensitive
and -insensitive C-fibers and the TRPV1 receptor [18]
may explain the different effects observed in different
patients.
We observed only mild local side effects. Local swell-
ing at injection sites occurred in 3 patients and disap-
peared within 7 days (1 cases receiving 25 U, 1 cases
receiving 75 U, 1cases receiving 125 U). Muscle relax-
ation and facial asymmetry at injection sites occurred
in 10 patients and disappeared within 6–8 weeks (1 case
receiving 45 U, 2 case receiving 50 U, 1 case receiving
70 U, 2 case receiving 75 U, 2 case receiving 100 U, 1
case receiving 120 U, 1 case receiving 125 U), which
may have been due to the diffusion of BTX-A into dee-
per layers of facial muscles as well as the induction of
transient muscle paralysis. All side effects were mild
and disappeared without the requirement for special
treatment.
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with effective treatment reported that they were “much
improved” or “very much improved” each month. That
means the treatment not only improved the TN symp-
toms, but also showed an improvement in the quality of
life, emotional function, side effect burden. So, we
think the subcutaneous injection of BTX-A for treating
TN is a clinical trial achieved a good satisfaction out of
participants’ aggregation all of the components of their
experience—pain relief, improvement in physical and
emotional functioning, side effects and so on.
And for those patients who have lost the injection effi-
cacy, 10 patients choose the surgical treatment, 4 patients
received the medical treatment, and 40 patients received
re-injection.Conclusion
In conclusion, we found that local subcutaneous injec-
tion of BTX-A for treating TN had considerable benefi-
cial effects lasting for several months and was safe to
use for this indication. One-quarter of patients could
reach complete control of pain for >14 months, and
maintenance of the therapeutic effect was related to a
reduction in the extent of the VAS score after the first
injection.
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